Literature DB >> 89310

Pharmacologically effective plasma concentrations of ranitidine.

N R Peden, D A Richards, J H Saunders, K G Wormsley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 89310     DOI： 10.1016/s0140-6736(79)91466-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  17 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy.

Authors:  P J Prichard; D B Jones; N D Yeomans; G W Mihaly; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

4.  Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.

Authors:  A M van Hecken; T B Tjandramaga; A Mullie; R Verbesselt; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

5.  Effects of eight weeks' continuous treatment with oral ranitidine and cimetidine on gastric acid secretion, pepsin secretion, and fasting serum gastrin.

Authors:  R Mohammed; R J Holden; J B Hearns; B M McKibben; K D Buchanan; G P Crean
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

6.  Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships.

Authors:  M Mignon; N P Chau; B K Nguyen-Phuoc; M Sauvage; F Leguy; S Bonfils
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 7.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

8.  Pharmacokinetics of the H2- receptor antagonist ranitidine in man.

Authors:  J J McNeil; G W Mihaly; A Anderson; A W Marshall; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

10.  Kinetics of rate controlled rectally administered ranitidine to male volunteers.

Authors:  H De Bree; A G De Boer
Journal:  Pharm Weekbl Sci       Date:  1987-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.